Clinical trials | Regimens | Diseases | Responses | References |
|---|
Phase Ib | V + R | R/R CLL | ORR—88 % |
86, 87
|
CR/CRi—32 % |
PR—56 % |
Phase I | V + BR | R/R NHL | ORR—61.5 % |
89
|
Phase Ib | V + BR | R/R CLL | Not reported |
90
|
Untreated CLL |
Phase Ib | V + O | R/R CLL | Not reported |
91
|
Untreated CLL |
-
R/R relapsed/refractory, ORR overall response rate, CLL chronic lymphoid leukemia, NHL non-Hodgkin’s lymphoma, AML acute myeloid leukemia. For regimens: V venetoclax, R rituximab, B bendamustine, O obinutuzumab
